MX2020004771A - Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. - Google Patents

Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Info

Publication number
MX2020004771A
MX2020004771A MX2020004771A MX2020004771A MX2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A
Authority
MX
Mexico
Prior art keywords
methods
gemcitabine
treatment
maintenance therapy
bladder cancer
Prior art date
Application number
MX2020004771A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Cutie
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2020004771A publication Critical patent/MX2020004771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
MX2020004771A 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. MX2020004771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08
PCT/US2018/059698 WO2019094517A1 (en) 2017-11-08 2018-11-07 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Publications (1)

Publication Number Publication Date
MX2020004771A true MX2020004771A (es) 2020-10-19

Family

ID=66439297

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Country Status (18)

Country Link
US (3) US10792297B2 (https=)
EP (1) EP3706763A4 (https=)
JP (2) JP2021502347A (https=)
KR (3) KR102892737B1 (https=)
CN (1) CN111787926A (https=)
AU (1) AU2018366106B2 (https=)
BR (1) BR112020008700A2 (https=)
CA (1) CA3081839A1 (https=)
DO (1) DOP2023000155A (https=)
EA (1) EA202091143A1 (https=)
IL (2) IL302714B1 (https=)
JO (1) JOP20200124A1 (https=)
MA (1) MA50581A (https=)
MX (2) MX2020004771A (https=)
PE (1) PE20210041A1 (https=)
PH (1) PH12020550587A1 (https=)
SG (1) SG11202003950WA (https=)
WO (1) WO2019094517A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
IL302714B1 (en) * 2017-11-08 2026-01-01 Taris Biomedical Llc Methods for treating and maintaining bladder cancer using gemcitabine
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
WO2009139984A2 (en) 2008-04-04 2009-11-19 Lipella Pharmaceuticals, Inc. Method of treatment for bladder dysfunction
AU2003278881A1 (en) 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
US20040260272A1 (en) 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
WO2011089604A2 (en) 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
CA2801314A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
DK2600800T3 (da) 2010-08-05 2020-11-16 Taris Biomedical Llc Indretning til lægemiddellevering i en ureterstent og kit dertil
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
CN105997967B (zh) 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
WO2012079083A2 (en) 2010-12-10 2012-06-14 The Board Of Regents Of The University Of Nebraska Hemodialysis catheter with displaceable tubes to disrupt a fibrous sheath
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9114111B2 (en) 2011-01-10 2015-08-25 Allergan, Inc. Methods for sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en) 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
JP6639228B2 (ja) 2012-03-29 2020-02-05 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
JP6463266B2 (ja) 2012-08-31 2019-01-30 タリス バイオメディカル エルエルシー 膀胱癌の治療のためのオキサリプラチンを含む薬物送達システム及び方法
AU2013308465B2 (en) 2012-08-31 2018-05-17 Taris Biomedical Llc Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
JP6697376B2 (ja) 2013-03-15 2020-05-20 タリス バイオメディカル エルエルシー 薬物送達のための薬物送達装置及び方法
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
CN113413393B (zh) 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
US9215250B2 (en) 2013-08-20 2015-12-15 Janus Technologies, Inc. System and method for remotely managing security and configuration of compute devices
BR112016010103A8 (pt) 2013-11-05 2018-01-30 Taris Biomedical Llc métodos, kits e dispositivos de suprimento de fármaco osmótico.
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
JP6856380B2 (ja) 2014-06-26 2021-04-07 タリス バイオメディカル エルエルシー 弾性ポリマー−薬物マトリックス系を含む膀胱内薬物送達デバイス及び方法
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
CN118453872A (zh) 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
IL302714B1 (en) * 2017-11-08 2026-01-01 Taris Biomedical Llc Methods for treating and maintaining bladder cancer using gemcitabine
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Also Published As

Publication number Publication date
IL302714B1 (en) 2026-01-01
BR112020008700A2 (pt) 2020-10-27
EP3706763A1 (en) 2020-09-16
PH12020550587A1 (en) 2021-04-26
MA50581A (fr) 2020-09-16
SG11202003950WA (en) 2020-05-28
KR20240119176A (ko) 2024-08-06
CA3081839A1 (en) 2019-05-16
JP2024009888A (ja) 2024-01-23
EA202091143A1 (ru) 2020-07-30
IL302714A (en) 2023-07-01
US20230321129A1 (en) 2023-10-12
KR102892737B1 (ko) 2025-11-28
KR20250174098A (ko) 2025-12-11
US20190175637A1 (en) 2019-06-13
KR20200085822A (ko) 2020-07-15
US20210085705A1 (en) 2021-03-25
IL274343B2 (en) 2023-10-01
IL274343B1 (en) 2023-06-01
AU2018366106B2 (en) 2024-11-14
IL274343A (en) 2020-06-30
MX2023007680A (es) 2023-07-07
WO2019094517A1 (en) 2019-05-16
AU2018366106A1 (en) 2020-05-14
CN111787926A (zh) 2020-10-16
DOP2023000155A (es) 2023-12-29
JP2021502347A (ja) 2021-01-28
EP3706763A4 (en) 2021-08-11
US10792297B2 (en) 2020-10-06
JOP20200124A1 (ar) 2020-05-20
PE20210041A1 (es) 2021-01-08
US12029749B2 (en) 2024-07-09

Similar Documents

Publication Publication Date Title
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX387283B (es) Tratamiento del cancer con tg02.
ECSP17073743A (es) Moduladores de k-ras
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX388914B (es) Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX373231B (es) Agente anticancerigeno.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2019001224A (es) Metodos para tratar el cancer de prostata.
ECSP17014159A (es) Terapia adjuntiva con 25-hidroxi vitamina d
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
TW201613587A (en) Medical treatments based on anamorelin
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
MX2020001727A (es) Terapia de combinacion.
MX2015011671A (es) Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.